NCT02248792

Methods	RCT, active‐controlled, double‐blind trial, phase 3 Date of study: November 2013‐January 2015 Location: India
Participants	Randomised: 50 participants Inclusion criteria Age range 18‐65 years Both sexes Severe plaque‐type psoriasis (BSA > 10% or PASI > 12) Exclusion criteria Pregnancy Lactation Malignancy or immunosuppression including HIV Liver disease Renal disease Non compliant Psychiatric illness Hypersensitivity to methotrexate in the past
Interventions	Intervention Methotrexate 10 mg/week Control intervention Methotrexate 25 mg/week
Outcomes	At week 12 Primary outcome Improvement in health related quality of life Secondary outcomes Comparison of improvement in health related quality of life between Group A and Group B
Notes	On ClinicalTrials.gov, Estimated Enrollment: 50 Study start date: November 2013 Estimated primary completion date: January 2015 (final data collection date for primary outcome measure) Emails sent to Prof. Krishna (5 and 12 January 2017)